Allotransplantation

MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3

Retrieved on: 
Wednesday, July 20, 2022

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.

Key Points: 
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process.
  • We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts.
  • MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer

Retrieved on: 
Monday, July 18, 2022

MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the addition of Kate Surdez as Chief Human Resources Officer (CHRO), effective today. Ms. Surdez comes to MIMEDX with more than 20 years of experience in Human Resources, having led talent acquisition, total rewards, succession and workforce planning, performance coaching, and organizational change management for several successful IPOs and large multinational biotech companies.

Key Points: 
  • MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced the addition of Kate Surdez as Chief Human Resources Officer (CHRO), effective today.
  • Timothy R. Wright, MIMEDX Chief Executive Officer, commented, Kate is a seasoned executive with a passion for life sciences.
  • I am thrilled to join MIMEDX to contribute to the collective success of each and every employee, Ms. Surdez added.
  • Kate is an accomplished Human Resources (HR) leader who has managed several organizations through growth and transformation.

ALLOSOURCE® ADDS QUADRICEP TENDONS TO ITS ALLOCONNEX™ LINE OF TENDONS, LIGAMENTS AND FASCIA

Retrieved on: 
Tuesday, July 12, 2022

AlloSource is introducing a new AlloConnex quadricep tendon, available with or without the bone block.

Key Points: 
  • AlloSource is introducing a new AlloConnex quadricep tendon, available with or without the bone block.
  • AlloSource's AlloConnex quadricep tendon is a robust option for cruciate ligament procedures and is available with or without the bone block for various surgical techniques.
  • AlloConnex tendons, ligaments and fascia are cleansed in AlloSource's unique, proprietary, patented cleansing process, AlloTrue.
  • To learn more about AlloSource's AlloConnex tendons, ligaments and fascia, please visit allosource.org/products/alloconnex or visit us at the annual AOSSM meeting in Colorado Springs, July 14-16, 2022, booth 616.

Tides Medical Announces Launch of Artacent AC for Complex Wounds

Retrieved on: 
Tuesday, July 5, 2022

LAFAYETTE, La., July 05, 2022 (GLOBE NEWSWIRE) -- Biologics company Tides Medical announces the launch of a new product, Artacent AC , a tri-layer skin graft designed for use in the treatment of complex or difficult-to-treat wounds.

Key Points: 
  • LAFAYETTE, La., July 05, 2022 (GLOBE NEWSWIRE) -- Biologics company Tides Medical announces the launch of a new product, Artacent AC , a tri-layer skin graft designed for use in the treatment of complex or difficult-to-treat wounds.
  • *
    Tides developed Artacent AC to offer clinicians a new and improved amniotic skin graft option featuring three layers (amnion-chorion-amnion) instead of the traditional two (amnion-amnion).
  • Tides' skin substitutes are used to treat a variety of medical conditions, including diabetic foot ulcers, chronic wounds, burns, Mohs surgery and various surgical applications.
  • "The development and launch of Artacent AC are part of our larger mission: revolutionizing access to the power of birth tissue technology."

Stem Cell Assays Market worth $4.5 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, June 21, 2022

The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.

Key Points: 
  • The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.
  • The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays.
  • The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021.
  • The stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells.

BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022

Retrieved on: 
Friday, June 17, 2022

About BioStem Technologies, Inc.(OTC PINK: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.

Key Points: 
  • About BioStem Technologies, Inc.(OTC PINK: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
  • The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain processing method.
  • BioStem Technologies quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB).
  • Each BioStem Technologies placental allograft is processed at the Companys FDA registered and AATB accredited site in Pompano Beach, Florida.

MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis

Retrieved on: 
Wednesday, June 15, 2022

MARIETTA, Ga., June 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced a collaboration agreement with Nordic Bioscience Clinical Development A/S (NBCD), a world-class Contract Research Organization (CRO) specializing in Osteoarthritis (OA) clinical trials. Image Analysis Group, an expert imaging company, will also provide advanced tools to detect the potential for the Company’s placental biologic injectable, micronized dehydrated Human Amnion Chorion Membrane (mdHACM), to act as a Disease Modifying Osteoarthritis Drug (DMOAD) and potentially moderate the progression of OA. The Company plans to initiate its registrational Knee Osteoarthritis (KOA) clinical trial program later this year, using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and WOMAC Function as co-primary endpoints.

Key Points: 
  • MARIETTA, Ga., June 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced a collaboration agreement with Nordic Bioscience Clinical Development A/S (NBCD), a world-class Contract Research Organization (CRO) specializing in Osteoarthritis (OA) clinical trials.
  • The Company plans to initiate its registrational Knee Osteoarthritis (KOA) clinical trial program later this year, using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and WOMAC Function as co-primary endpoints.
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • NBCD specializes in design and execution of clinical trials within both pain and Disease-Modifying Osteoarthritis Drugs (DMOAD) compounds for osteoarthritis.

Biologic Therapies for Wound Care Technologies and Global Markets Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 13, 2022

The "Biologic Therapies for Wound Care: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biologic Therapies for Wound Care: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report studies the global market for wound care biologics.
  • Biological therapies are an emerging approach in modern wound care, as they can stimulate the body's own natural healing power by activating its inherent ability to repair and regenerate.
  • Wound care biologics manufacturers are investing in educating healthcare professionals and clinicians about the clinical and cost advantages of biologics in wound care.

Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A

Retrieved on: 
Monday, June 13, 2022

ASC Therapeutics has received IND clearance , as well as key regulatory designations in the U.S. and Europe for its ASC618 program.

Key Points: 
  • ASC Therapeutics has received IND clearance , as well as key regulatory designations in the U.S. and Europe for its ASC618 program.
  • Since 2019, ASC Therapeutics has worked with Charles River, previously Vigene Biosciences, to leverage the Companys industry-leading expertise in Good Manufacturing Practice (GMP)-virus manufacturing, and established processes for AAV production and purification.
  • We are proud to work with ASC Therapeutics as they progress their second-generation gene therapy program for hemophilia A to clinical stage.
  • ASC Therapeutics is a biopharmaceutical company pioneering the development of gene replacement therapies, in vivo gene editing and allogeneic cell therapies for hematological, metabolic, and other rare diseases.

Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners

Retrieved on: 
Thursday, June 9, 2022

SINGAPORE, June 09, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the close of a US$126 million Series A financing round. Polaris Partners led the financing with participation from existing investors, including Temasek, EDBI, Heliconia Capital and Heritas Capital. In conjunction with the financing, Amy Schulman and Darren Carroll, Managing Partners at Polaris Partners, have joined Tessa’s Board of Directors.

Key Points: 
  • Polaris Partners led the financing with participation from existing investors, including Temasek, EDBI, Heliconia Capital and Heritas Capital.
  • In conjunction with the financing, Amy Schulman and Darren Carroll, Managing Partners at Polaris Partners, have joined Tessas Board of Directors.
  • We are very pleased to have secured this significant round of financing from such a highly regarded syndicate of global healthcare investors, including Temasek and Polaris Partners, said Gran Ando, M.D., Chairman of the Board of Tessa Therapeutics.
  • We are delighted to lead this financing in Tessa Therapeutics to enable the acceleration of the company's corporate and clinical development activities, said Ms. Schulman.